 Linda Barbour
Concepts (329)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes, Gestational | 33 | 2024 | 321 | 9.310 |
Why?
| | Pregnancy Complications | 15 | 2026 | 592 | 2.730 |
Why?
| | Obesity | 22 | 2026 | 3085 | 2.440 |
Why?
| | Adiposity | 12 | 2024 | 545 | 2.390 |
Why?
| | Pregnancy | 71 | 2026 | 7208 | 2.300 |
Why?
| | Blood Glucose | 18 | 2024 | 2333 | 1.960 |
Why?
| | Pregnancy in Diabetics | 7 | 2025 | 121 | 1.910 |
Why?
| | Insulin Resistance | 15 | 2023 | 1243 | 1.900 |
Why?
| | Glyburide | 5 | 2018 | 31 | 1.860 |
Why?
| | Fetal Development | 6 | 2018 | 299 | 1.560 |
Why?
| | Metformin | 4 | 2018 | 320 | 1.420 |
Why?
| | Postprandial Period | 4 | 2026 | 118 | 1.390 |
Why?
| | Pregnancy Outcome | 14 | 2025 | 480 | 1.370 |
Why?
| | Hypoglycemic Agents | 9 | 2024 | 1391 | 1.310 |
Why?
| | Fetal Macrosomia | 4 | 2019 | 62 | 1.220 |
Why?
| | Infant, Newborn | 30 | 2024 | 6456 | 1.200 |
Why?
| | Diet, Fat-Restricted | 3 | 2023 | 79 | 1.040 |
Why?
| | Insulin | 16 | 2024 | 2507 | 1.010 |
Why?
| | Obstetrics | 3 | 2024 | 175 | 1.000 |
Why?
| | Diet, Diabetic | 3 | 2015 | 33 | 0.960 |
Why?
| | Diabetes Mellitus, Type 2 | 10 | 2025 | 2592 | 0.920 |
Why?
| | Birth Weight | 12 | 2021 | 524 | 0.900 |
Why?
| | Triglycerides | 5 | 2026 | 521 | 0.890 |
Why?
| | Practice Guidelines as Topic | 4 | 2024 | 1568 | 0.880 |
Why?
| | Body Composition | 7 | 2017 | 708 | 0.780 |
Why?
| | Female | 75 | 2026 | 78605 | 0.780 |
Why?
| | Thyroid Crisis | 1 | 2022 | 8 | 0.740 |
Why?
| | Placenta | 5 | 2022 | 781 | 0.680 |
Why?
| | Abortion, Spontaneous | 2 | 2021 | 115 | 0.670 |
Why?
| | Lipids | 2 | 2018 | 712 | 0.670 |
Why?
| | Pregnancy Complications, Cardiovascular | 5 | 2004 | 83 | 0.640 |
Why?
| | Diabetic Ketoacidosis | 1 | 2022 | 210 | 0.600 |
Why?
| | Blood Glucose Self-Monitoring | 4 | 2024 | 699 | 0.600 |
Why?
| | Maternal Nutritional Physiological Phenomena | 6 | 2020 | 181 | 0.580 |
Why?
| | Humans | 79 | 2026 | 145307 | 0.570 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2021 | 180 | 0.540 |
Why?
| | Nutrition Therapy | 1 | 2018 | 37 | 0.530 |
Why?
| | Lipoprotein Lipase | 1 | 2018 | 56 | 0.530 |
Why?
| | Growth Hormone | 4 | 2007 | 92 | 0.510 |
Why?
| | Plethysmography | 3 | 2016 | 109 | 0.500 |
Why?
| | Milk, Human | 5 | 2021 | 172 | 0.500 |
Why?
| | Thromboembolism | 4 | 2001 | 125 | 0.500 |
Why?
| | Premature Birth | 1 | 2021 | 384 | 0.490 |
Why?
| | Mass Screening | 2 | 2024 | 1357 | 0.480 |
Why?
| | Societies, Medical | 5 | 2025 | 893 | 0.460 |
Why?
| | Insulin Receptor Substrate Proteins | 4 | 2011 | 55 | 0.460 |
Why?
| | Muscle, Skeletal | 5 | 2014 | 1800 | 0.450 |
Why?
| | Absorptiometry, Photon | 2 | 2015 | 276 | 0.440 |
Why?
| | Preconception Care | 2 | 2025 | 50 | 0.440 |
Why?
| | Fatty Acids, Nonesterified | 6 | 2019 | 158 | 0.440 |
Why?
| | Lipid Metabolism | 1 | 2018 | 529 | 0.430 |
Why?
| | Mothers | 8 | 2018 | 776 | 0.430 |
Why?
| | Hyperglycemia | 2 | 2019 | 376 | 0.430 |
Why?
| | Maternal-Child Health Centers | 1 | 2014 | 8 | 0.430 |
Why?
| | Pregnancy Proteins | 3 | 2021 | 35 | 0.420 |
Why?
| | Phosphatidylinositol 3-Kinases | 3 | 2007 | 381 | 0.420 |
Why?
| | Prenatal Exposure Delayed Effects | 3 | 2020 | 675 | 0.410 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1098 | 0.400 |
Why?
| | Adipose Tissue | 5 | 2018 | 653 | 0.400 |
Why?
| | Dietary Fiber | 1 | 2013 | 59 | 0.390 |
Why?
| | Adult | 31 | 2026 | 40627 | 0.390 |
Why?
| | Dietary Carbohydrates | 1 | 2014 | 151 | 0.390 |
Why?
| | Breast Feeding | 5 | 2024 | 448 | 0.370 |
Why?
| | Monitoring, Ambulatory | 1 | 2012 | 89 | 0.360 |
Why?
| | Heparin | 5 | 2001 | 244 | 0.360 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 2182 | 0.340 |
Why?
| | Glucose Tolerance Test | 6 | 2021 | 361 | 0.340 |
Why?
| | Glucose | 4 | 2023 | 1049 | 0.340 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2011 | 36 | 0.330 |
Why?
| | Fasting | 5 | 2026 | 277 | 0.330 |
Why?
| | Prenatal Care | 5 | 2025 | 307 | 0.320 |
Why?
| | Fatty Liver | 1 | 2012 | 251 | 0.310 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2012 | 631 | 0.310 |
Why?
| | Prospective Studies | 9 | 2024 | 8011 | 0.310 |
Why?
| | Anticoagulants | 5 | 2004 | 726 | 0.300 |
Why?
| | Glucose Intolerance | 1 | 2011 | 142 | 0.300 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2014 | 909 | 0.290 |
Why?
| | Diabetes Mellitus, Type 1 | 4 | 2025 | 3906 | 0.270 |
Why?
| | Infant | 9 | 2024 | 10101 | 0.270 |
Why?
| | Muscle Proteins | 2 | 2014 | 244 | 0.270 |
Why?
| | Inflammation | 2 | 2018 | 2881 | 0.260 |
Why?
| | Postpartum Period | 7 | 2020 | 369 | 0.260 |
Why?
| | Endocrinology | 2 | 2025 | 77 | 0.260 |
Why?
| | Gestational Age | 3 | 2020 | 980 | 0.250 |
Why?
| | Pregnancy Complications, Hematologic | 2 | 2017 | 24 | 0.240 |
Why?
| | Diet | 5 | 2024 | 1285 | 0.240 |
Why?
| | Gastrointestinal Microbiome | 3 | 2020 | 772 | 0.240 |
Why?
| | Prenatal Nutritional Physiological Phenomena | 3 | 2017 | 59 | 0.230 |
Why?
| | Placental Hormones | 2 | 2003 | 4 | 0.230 |
Why?
| | United States | 8 | 2024 | 16051 | 0.230 |
Why?
| | Venous Thrombosis | 2 | 2004 | 195 | 0.220 |
Why?
| | Metabolic Diseases | 1 | 2026 | 114 | 0.220 |
Why?
| | Lactation | 3 | 2021 | 192 | 0.220 |
Why?
| | Dalteparin | 1 | 2004 | 10 | 0.210 |
Why?
| | Glycemic Index | 2 | 2015 | 26 | 0.210 |
Why?
| | Nutritional Status | 2 | 2024 | 354 | 0.210 |
Why?
| | Malnutrition | 1 | 2024 | 86 | 0.190 |
Why?
| | Random Allocation | 1 | 2023 | 363 | 0.190 |
Why?
| | C-Peptide | 1 | 2023 | 189 | 0.180 |
Why?
| | Gynecology | 1 | 2024 | 178 | 0.180 |
Why?
| | Patient Compliance | 3 | 2015 | 589 | 0.170 |
Why?
| | Microbiota | 2 | 2022 | 781 | 0.170 |
Why?
| | Societies, Nursing | 1 | 2001 | 27 | 0.170 |
Why?
| | Emergencies | 1 | 2022 | 176 | 0.170 |
Why?
| | Interinstitutional Relations | 1 | 2001 | 53 | 0.170 |
Why?
| | Life Style | 1 | 2024 | 483 | 0.170 |
Why?
| | Labor, Obstetric | 1 | 2001 | 67 | 0.160 |
Why?
| | Hyperinsulinism | 1 | 2021 | 113 | 0.160 |
Why?
| | Nurse Midwives | 1 | 2001 | 44 | 0.160 |
Why?
| | Mammary Glands, Human | 1 | 2020 | 67 | 0.160 |
Why?
| | Pediatric Obesity | 2 | 2020 | 645 | 0.160 |
Why?
| | Infant Formula | 1 | 2020 | 71 | 0.160 |
Why?
| | Magnetic Resonance Imaging | 1 | 2012 | 3888 | 0.160 |
Why?
| | Risk | 1 | 2022 | 912 | 0.150 |
Why?
| | Risk Factors | 6 | 2018 | 10816 | 0.150 |
Why?
| | Pregnancy Trimester, First | 2 | 2018 | 136 | 0.150 |
Why?
| | Delivery, Obstetric | 2 | 2017 | 160 | 0.150 |
Why?
| | Safety | 1 | 2001 | 356 | 0.150 |
Why?
| | Sleep Apnea Syndromes | 1 | 2020 | 97 | 0.140 |
Why?
| | Male | 16 | 2021 | 72629 | 0.140 |
Why?
| | Signal Transduction | 3 | 2011 | 5239 | 0.140 |
Why?
| | Body Mass Index | 6 | 2020 | 2439 | 0.140 |
Why?
| | Awards and Prizes | 1 | 2019 | 72 | 0.140 |
Why?
| | Weight Loss | 1 | 2024 | 838 | 0.130 |
Why?
| | Body Weight | 3 | 2015 | 980 | 0.130 |
Why?
| | Niacin | 1 | 2017 | 16 | 0.130 |
Why?
| | Heparin, Low-Molecular-Weight | 3 | 2004 | 36 | 0.130 |
Why?
| | Analgesia, Obstetrical | 1 | 2017 | 32 | 0.130 |
Why?
| | Anesthesia, Obstetrical | 1 | 2017 | 30 | 0.130 |
Why?
| | Anemia, Aplastic | 1 | 2017 | 42 | 0.130 |
Why?
| | Glucose Transporter Type 1 | 1 | 2017 | 48 | 0.130 |
Why?
| | Carrier Proteins | 1 | 2021 | 739 | 0.130 |
Why?
| | Protein S Deficiency | 1 | 1996 | 8 | 0.120 |
Why?
| | Reference Values | 3 | 2007 | 798 | 0.120 |
Why?
| | Protein S | 1 | 1996 | 11 | 0.120 |
Why?
| | Complement Inactivator Proteins | 1 | 1996 | 39 | 0.120 |
Why?
| | Fatty Acids, Omega-6 | 1 | 2016 | 48 | 0.120 |
Why?
| | Thrombolytic Therapy | 1 | 1997 | 163 | 0.120 |
Why?
| | Fetal Weight | 1 | 2016 | 54 | 0.120 |
Why?
| | Adipogenesis | 1 | 2016 | 57 | 0.120 |
Why?
| | Heart Valve Diseases | 1 | 1997 | 151 | 0.120 |
Why?
| | Umbilical Cord | 1 | 2016 | 91 | 0.120 |
Why?
| | Phosphorylation | 3 | 2014 | 1735 | 0.120 |
Why?
| | Niacinamide | 1 | 2016 | 86 | 0.120 |
Why?
| | Diet, High-Fat | 1 | 2017 | 262 | 0.120 |
Why?
| | Computational Biology | 1 | 2020 | 683 | 0.120 |
Why?
| | Mice, Transgenic | 4 | 2007 | 2192 | 0.110 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2018 | 266 | 0.110 |
Why?
| | Thrombophilia | 2 | 2009 | 88 | 0.110 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2016 | 142 | 0.110 |
Why?
| | Metabolic Syndrome | 1 | 2019 | 356 | 0.110 |
Why?
| | Pandemics | 1 | 2024 | 1698 | 0.110 |
Why?
| | Placenta Growth Factor | 2 | 2005 | 26 | 0.110 |
Why?
| | Anthropometry | 1 | 2015 | 200 | 0.110 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2019 | 300 | 0.110 |
Why?
| | Trophoblasts | 1 | 2017 | 217 | 0.110 |
Why?
| | Antigens | 1 | 1996 | 347 | 0.110 |
Why?
| | Leptin | 1 | 2016 | 247 | 0.110 |
Why?
| | Glycoproteins | 1 | 1996 | 355 | 0.110 |
Why?
| | Europe | 2 | 2025 | 416 | 0.100 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2014 | 37 | 0.100 |
Why?
| | Phosphoproteins | 3 | 2007 | 346 | 0.100 |
Why?
| | Ultrasonography, Prenatal | 1 | 2016 | 294 | 0.100 |
Why?
| | Fetus | 1 | 2018 | 803 | 0.100 |
Why?
| | Dietary Sucrose | 1 | 2013 | 49 | 0.100 |
Why?
| | Maternal-Fetal Exchange | 1 | 2014 | 169 | 0.100 |
Why?
| | Young Adult | 4 | 2018 | 14163 | 0.100 |
Why?
| | Fructose | 1 | 2013 | 132 | 0.100 |
Why?
| | Caloric Restriction | 1 | 2014 | 127 | 0.100 |
Why?
| | Patient Care Planning | 1 | 1994 | 171 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2118 | 0.090 |
Why?
| | Case-Control Studies | 2 | 2018 | 3613 | 0.090 |
Why?
| | Patient Education as Topic | 1 | 2018 | 782 | 0.090 |
Why?
| | Calcium Signaling | 1 | 2014 | 252 | 0.090 |
Why?
| | Thrombocytopenia | 1 | 1994 | 205 | 0.090 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 263 | 0.090 |
Why?
| | Thyroid Diseases | 1 | 2012 | 44 | 0.090 |
Why?
| | Puerperal Disorders | 1 | 2012 | 37 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2020 | 1747 | 0.090 |
Why?
| | Hyperthyroidism | 2 | 2012 | 21 | 0.090 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 2609 | 0.090 |
Why?
| | Biomedical Research | 1 | 2018 | 713 | 0.090 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2005 | 319 | 0.090 |
Why?
| | Cross-Over Studies | 1 | 2014 | 610 | 0.090 |
Why?
| | Prognosis | 2 | 2018 | 4310 | 0.080 |
Why?
| | Health Promotion | 1 | 2018 | 777 | 0.080 |
Why?
| | Osteoporosis | 1 | 1994 | 236 | 0.080 |
Why?
| | Weight Gain | 3 | 2021 | 564 | 0.080 |
Why?
| | Overweight | 1 | 2015 | 610 | 0.080 |
Why?
| | Serine | 1 | 2011 | 145 | 0.080 |
Why?
| | Tyrosine | 1 | 2011 | 222 | 0.080 |
Why?
| | Thrombosis | 1 | 1994 | 398 | 0.080 |
Why?
| | Bone Density | 1 | 1994 | 484 | 0.080 |
Why?
| | Software | 1 | 2015 | 693 | 0.080 |
Why?
| | Pilot Projects | 1 | 2015 | 1894 | 0.070 |
Why?
| | Dietary Supplements | 1 | 2013 | 576 | 0.070 |
Why?
| | Motor Activity | 1 | 2014 | 725 | 0.070 |
Why?
| | BRCA2 Protein | 1 | 2009 | 67 | 0.070 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2009 | 64 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 983 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2014 | 11731 | 0.070 |
Why?
| | Warfarin | 2 | 2001 | 171 | 0.070 |
Why?
| | Blotting, Western | 1 | 2011 | 1187 | 0.070 |
Why?
| | Pulmonary Embolism | 2 | 2001 | 244 | 0.060 |
Why?
| | Prevalence | 1 | 2014 | 2838 | 0.060 |
Why?
| | Fatty Acids, Volatile | 2 | 2018 | 60 | 0.060 |
Why?
| | Hypothyroidism | 1 | 2007 | 67 | 0.060 |
Why?
| | Hormones | 1 | 2007 | 134 | 0.060 |
Why?
| | Diet Surveys | 2 | 2017 | 91 | 0.060 |
Why?
| | Cohort Studies | 4 | 2019 | 5982 | 0.060 |
Why?
| | Partial Thromboplastin Time | 2 | 1996 | 50 | 0.060 |
Why?
| | Mice | 5 | 2018 | 18397 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2004 | 2032 | 0.060 |
Why?
| | Time Factors | 2 | 2012 | 7186 | 0.060 |
Why?
| | Epigenesis, Genetic | 1 | 2010 | 687 | 0.060 |
Why?
| | Adipocytes | 1 | 2007 | 223 | 0.060 |
Why?
| | Treatment Failure | 1 | 2006 | 365 | 0.060 |
Why?
| | Protein Subunits | 1 | 2005 | 229 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2012 | 3419 | 0.050 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2005 | 269 | 0.050 |
Why?
| | Adolescent | 4 | 2018 | 22507 | 0.050 |
Why?
| | Cesarean Section | 1 | 2006 | 227 | 0.050 |
Why?
| | RNA | 1 | 2011 | 940 | 0.050 |
Why?
| | Feces | 2 | 2018 | 514 | 0.050 |
Why?
| | Point-of-Care Systems | 1 | 2026 | 187 | 0.050 |
Why?
| | Glucose Transporter Type 4 | 1 | 2003 | 38 | 0.050 |
Why?
| | Biomarkers | 2 | 2016 | 4284 | 0.050 |
Why?
| | Pre-Eclampsia | 1 | 2006 | 205 | 0.050 |
Why?
| | Evidence-Based Medicine | 2 | 2012 | 737 | 0.050 |
Why?
| | Monosaccharide Transport Proteins | 1 | 2003 | 56 | 0.050 |
Why?
| | Receptor, Insulin | 1 | 2003 | 94 | 0.050 |
Why?
| | Child | 3 | 2024 | 22712 | 0.050 |
Why?
| | Thyroid Neoplasms | 1 | 2007 | 349 | 0.050 |
Why?
| | Animals | 6 | 2018 | 38180 | 0.050 |
Why?
| | Bifidobacterium | 1 | 2022 | 21 | 0.050 |
Why?
| | Glycerol | 1 | 2022 | 90 | 0.050 |
Why?
| | Physician-Nurse Relations | 1 | 2001 | 18 | 0.040 |
Why?
| | Protein Structure, Tertiary | 1 | 2003 | 862 | 0.040 |
Why?
| | Organizational Objectives | 1 | 2001 | 67 | 0.040 |
Why?
| | Anesthesia, Conduction | 1 | 2001 | 43 | 0.040 |
Why?
| | Organizational Policy | 1 | 2001 | 76 | 0.040 |
Why?
| | Vegetables | 1 | 2021 | 170 | 0.040 |
Why?
| | Feeding Behavior | 2 | 2016 | 692 | 0.040 |
Why?
| | United Kingdom | 1 | 2001 | 338 | 0.040 |
Why?
| | Cell Membrane | 1 | 2003 | 708 | 0.040 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1054 | 0.040 |
Why?
| | Nurse's Role | 1 | 2001 | 170 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2017 | 2959 | 0.040 |
Why?
| | Germ-Free Life | 1 | 2018 | 33 | 0.040 |
Why?
| | National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2018 | 10 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2005 | 3129 | 0.030 |
Why?
| | Diet, Western | 1 | 2018 | 86 | 0.030 |
Why?
| | Polysomnography | 1 | 2019 | 236 | 0.030 |
Why?
| | Saliva | 1 | 2019 | 249 | 0.030 |
Why?
| | Fatty Acid Transport Proteins | 1 | 2017 | 22 | 0.030 |
Why?
| | England | 1 | 1997 | 111 | 0.030 |
Why?
| | Bile Acids and Salts | 1 | 2018 | 164 | 0.030 |
Why?
| | Sweden | 1 | 1997 | 111 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2018 | 249 | 0.030 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 359 | 0.030 |
Why?
| | Hydrocortisone | 1 | 2019 | 304 | 0.030 |
Why?
| | Dysbiosis | 1 | 2018 | 187 | 0.030 |
Why?
| | Factor V | 1 | 1996 | 26 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2020 | 1173 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2017 | 174 | 0.030 |
Why?
| | Lactobacillales | 1 | 2016 | 5 | 0.030 |
Why?
| | Gammaproteobacteria | 1 | 2016 | 13 | 0.030 |
Why?
| | Sirtuin 1 | 1 | 2016 | 34 | 0.030 |
Why?
| | Breast Neoplasms | 1 | 2009 | 2464 | 0.030 |
Why?
| | Pyruvate Kinase | 1 | 2016 | 28 | 0.030 |
Why?
| | Stem Cells | 1 | 2020 | 627 | 0.030 |
Why?
| | Pregnancy Trimester, Third | 1 | 2016 | 115 | 0.030 |
Why?
| | Receptors, Complement | 1 | 1996 | 125 | 0.030 |
Why?
| | Factor VIII | 1 | 1996 | 104 | 0.030 |
Why?
| | Factor Xa | 1 | 1995 | 35 | 0.030 |
Why?
| | Arm | 1 | 2016 | 110 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 1995 | 165 | 0.030 |
Why?
| | PPAR gamma | 1 | 2016 | 177 | 0.030 |
Why?
| | Pulmonary Alveoli | 1 | 1998 | 383 | 0.030 |
Why?
| | Stillbirth | 1 | 2015 | 79 | 0.030 |
Why?
| | Hemostasis | 1 | 1995 | 103 | 0.030 |
Why?
| | Adenylate Kinase | 1 | 2014 | 27 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2016 | 5883 | 0.030 |
Why?
| | Leg | 1 | 2016 | 239 | 0.030 |
Why?
| | Electron Transport | 1 | 2014 | 118 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2020 | 1126 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 851 | 0.030 |
Why?
| | Heart Valve Prosthesis | 1 | 1995 | 134 | 0.030 |
Why?
| | Bacteria | 1 | 2020 | 891 | 0.030 |
Why?
| | Linear Models | 1 | 2016 | 854 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 1995 | 784 | 0.020 |
Why?
| | Antibodies | 1 | 1995 | 403 | 0.020 |
Why?
| | Blood Coagulation Disorders | 1 | 1995 | 189 | 0.020 |
Why?
| | Energy Intake | 1 | 2016 | 508 | 0.020 |
Why?
| | Thyroiditis | 1 | 2012 | 4 | 0.020 |
Why?
| | Intestinal Mucosa | 1 | 2018 | 677 | 0.020 |
Why?
| | Oxygen | 1 | 1998 | 995 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1540 | 0.020 |
Why?
| | Femur | 1 | 1994 | 250 | 0.020 |
Why?
| | Lumbar Vertebrae | 1 | 1994 | 252 | 0.020 |
Why?
| | Sibling Relations | 1 | 1991 | 10 | 0.020 |
Why?
| | Child, Preschool | 2 | 2024 | 11863 | 0.020 |
Why?
| | Liver | 1 | 2018 | 1893 | 0.020 |
Why?
| | Mother-Child Relations | 1 | 1991 | 135 | 0.020 |
Why?
| | Pregnancy Trimester, Second | 1 | 2009 | 82 | 0.020 |
Why?
| | Intellectual Disability | 1 | 1991 | 175 | 0.020 |
Why?
| | Mastectomy, Segmental | 1 | 2009 | 108 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2009 | 267 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 187 | 0.020 |
Why?
| | Lymph Node Excision | 1 | 2009 | 174 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2006 | 17149 | 0.020 |
Why?
| | Mitochondria | 1 | 2014 | 987 | 0.020 |
Why?
| | Proteomics | 1 | 2014 | 1195 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2018 | 6009 | 0.020 |
Why?
| | Thyroid Hormones | 1 | 2007 | 68 | 0.020 |
Why?
| | Doxorubicin | 1 | 2009 | 398 | 0.020 |
Why?
| | 3T3 Cells | 1 | 2007 | 156 | 0.020 |
Why?
| | Colorado | 1 | 2016 | 4579 | 0.020 |
Why?
| | DNA Primers | 1 | 2007 | 512 | 0.010 |
Why?
| | Cattle | 1 | 2007 | 1001 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 6079 | 0.010 |
Why?
| | Down Syndrome | 1 | 1991 | 534 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1962 | 0.010 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 1998 | 12 | 0.010 |
Why?
| | Pulmonary Gas Exchange | 1 | 1998 | 119 | 0.010 |
Why?
| | Arteries | 1 | 1998 | 259 | 0.010 |
Why?
| | Gender Identity | 1 | 1991 | 121 | 0.000 |
Why?
| | Social Environment | 1 | 1991 | 254 | 0.000 |
Why?
| | Parenting | 1 | 1991 | 318 | 0.000 |
Why?
|
|
Barbour's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|